At 71 years old, facing a terminal diagnosis, Colorado resident Tom Pringle has one more thing he wants to do before he dies: help other people in similar situations by trying an experimental drug to ...

University of Utah researchers at the Pulst-Scoles Laboratory have discovered that reducing levels of the STAUFEN-1 protein ...

The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.

Researchers at VIB and KU Leuven have identified a molecular process that allows motor neurons to maintain protein production, a process that fails in amyotrophic lateral sclerosis (ALS).

In May 2022, The US FDA authorized the use of RADICAVA ORS (edaravone) in an oral formulation for the treatment of ALS.